Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 199

Sort by

Sort Order Select

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Rodney H Falk, MD, Morie A Gertz, MD, Merrill D Benson, MD, Gustavo Buchele, MD PhD, Michela Brambatti, MD MS, Sotirios Tsimikas, MD, Nicholas J Viney, Bsc, Li-Jung Tai, MD PhD, Cecilia Monteiro, MD PhD, Qingqing Yang, MS, Louis St L O'Dea, MB B.Ch. BAO, FRCP, Ewa Karwatowska-Prokopczuk, MD PhD, Eugene Schneider, MD, Richard S Geary, PhD, Brett P Monia, PhD

Blood (2019) 134 (Supplement_1): 5764.

https://doi.org/10.1182/blood-2019-129269

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Susanne Beck, Martina Emde, Jerome Moreaux, PhD, Anja Seckinger, Dirk Hose, MD

Blood (2019) 134 (Supplement_1): 3078.

https://doi.org/10.1182/blood-2019-131161

Published: 2019

Journal Articles

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Georg Jeryczynski, MD, Antonia Eder, Eva-Maria Reitter, MD, Maria-Theresa Krauth, MD, Hermine Agis, MD

Blood (2019) 134 (Supplement_1): 3123.

https://doi.org/10.1182/blood-2019-124681

Published: 2019

Journal Articles

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

Marco Basset, MD, Paolo Milani, MD PhD, Andrea Foli, MD, Mario Nuvolone, MD PhD, Jessica Ripepi, Margherita Bozzola, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 3312.

https://doi.org/10.1182/blood-2019-130364

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

A Machine Learning Algorithm to Improve Risk Assessment for Patients with Sickle Cell Disease

Vandana Sachdev, MD, Yuan Gu, PhD, James Nichols, RN, Wen Li, RCS, Stanislav Sidenko, RCS, Darlene Allen, MT(ASCP), Colin Wu, PhD, Swee Lay Thein, DSc, MBBS

Blood (2019) 134 (Supplement_1): 893.

https://doi.org/10.1182/blood-2019-125846

Published: 2019

Journal Articles

Non-Hematologic Therapy Toxicities Correlated with Survival, Drug Discontinuation and Response in Multiple Myeloma Patients: A Retrospective Study

Weimin Huang, PhD, Yongqiang Wei, PhD, Jingxia Zheng, Xiaolei Wei, PhD, Ru Feng, MD

Blood (2019) 134 (Supplement_1): 5496.

https://doi.org/10.1182/blood-2019-126751

Published: 2019

Journal Articles

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, David Iberri, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Richard Lafayette, MD, Sally Arai, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1884.

https://doi.org/10.1182/blood-2019-124981

Published: 2019

Journal Articles

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

Alfred Chung, MD, Gregory P. Kaufman, MD, Surbhi Sidana, MD, Erik Eckhert, MD MS, Stanley Schrier, MD, Sally Arai, MD, Richard Lafayette, MD, Ronald Witteles, MD, Michaela Liedtke, MD

Blood (2019) 134 (Supplement_1): 1828.

https://doi.org/10.1182/blood-2019-122152

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Eftathios Kastritis, Monique C. Minnema, Meletios A. Dimopoulos, MD, Giampaolo Merlini, MD, Pieter Sonneveld, Giovanni Palladini, MD PhD

Blood (2019) 134 (Supplement_1): 1868.

https://doi.org/10.1182/blood-2019-126524

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Marta Alonso Fernández de Gatta, MD PhD, Ana Martín García, MD PhD, Félix López Cadenas, MD, Díaz Peláez Elena, MD, Tamara Jimenez, Jesus Maria . Hernández-Rivas, MD, Victor Vallejo García, MD, Manuel Barreiro Pérez, MD, Lucia Rodríguez Estévez, MD, Juan Carlos Castro Garay, Diego Ávila, MD, Adolfo Alejandro Cabanillas Cabral, MD, Clara Sánchez Pablo, MD, María Díez-Campelo, MD PhD, Pedro Luís Sánchez Fernández, MD PhD

Blood (2019) 134 (Supplement_1): 1727.

https://doi.org/10.1182/blood-2019-127938

Published: 2019

Journal Articles

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay

Eli Muchtar, Shaji K. Kumar, Morie A. Gertz, Martha Grogan, Omar F. AbouEzzeddine, Allan S. Jaffe, Angela Dispenzieri

Blood (2019) 133 (7): 763–766.

https://doi.org/10.1182/blood-2018-10-875252

Published: 2019

Includes: Supplemental data

Journal Articles

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis

Brian Lilleness, Frederick L. Ruberg, Roberta Mussinelli, Gheorghe Doros, Vaishali Sanchorawala

Blood (2019) 133 (3): 215–223.

https://doi.org/10.1182/blood-2018-06-858951

Published: 2019

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Divaya Bhutani, MD, Siyang Leng, MD, Andrew Eisenberger, MD, Mathew S. Maurer, MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 958.

https://doi.org/10.1182/blood-2018-99-118464

Published: 2018

Journal Articles

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Richa Manwani, MBBS, FRCPath, BSc, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2018-99-116688

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

AL patients don’t dare go without dara

Rationale and Design of a Phase 3 Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Prediction of Malingant Plasma Cell Biology Related Survival in AL-Amyloidosis

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Sequential Therapy with Cyclophosphamide, Bortezomib and Dexamethasone Followed By Autologous Stem Cell Transplant Is Safe and Highly Effective in AL Amyloidosis

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

A Machine Learning Algorithm to Improve Risk Assessment for Patients with Sickle Cell Disease

Non-Hematologic Therapy Toxicities Correlated with Survival, Drug Discontinuation and Response in Multiple Myeloma Patients: A Retrospective Study

Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses

Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN)

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Transfusion-Dependent Low Risk Myelodysplastic Syndrome (TD LR-MDS): Predictors Ofcardiovascular Events and Death

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay

Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only